Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

1990 • 3,817 citations

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

1992 • 1,063 citations

Apoptotic cell death induced by c-myc is inhibited by bcl-2

1992 • 981 citations

Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.

1990 • 926 citations

Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line

1993 • 898 citations

Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.

1993 • 875 citations

Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland

1977 • 633 citations

Toward an understanding of the molecular mechanisms of physiological cell death.

1993 • 623 citations

bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer

1994 • 326 citations

Expression in Non-Hodgkin's Lymphoma of thebcl-2 Protein Associated with the t(14;18) Chromosomal Translocation

1988 • 292 citations

bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells

1992 • 276 citations

BCL‐2 expression in adult and embryonic non‐haematopoietic tissues

1993 • 265 citations

Expression of bcl-2 in small cell lung carcinoma cells.

1994 • 222 citations

Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2.

1993 • 214 citations

Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival

1993 • 185 citations

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity

1993 • 183 citations

The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status

1994 • 126 citations

Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival.

1980 • 119 citations

ASSESSMENT OF RESPONSE TO TREATMENT IN ADVANCED BREAST CANCER

1974 • 81 citations

Advances in Immunohistochemistry

1989 • 77 citations

Hormone sensitivity in breast cancer: Influence of heterogeneity of oestrogen receptor expression and cell proliferation

1991 • 74 citations

Transforming growth factor-alpha and endocrine sensitivity in breast cancer.

1994 • 64 citations

Role of bcl-2 in growth factor triggered signal transduction.

1990 • 13 citations

Short term tamoxifen induces the cytoplasmic expression of c-erbB2 and BCL-2 in er-positive human primary breast cancer

1992 • 8 citations